Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12454224 | 0.91 | FDPS (0.33) | — | |
| SCHEMBL13616906 | 0.86 | PIK3CD (0.31) | PIK3CDMEN1KMT2A | |
| SCHEMBL15243830 | 0.81 | GRM4 (0.32) | PIK3CDMEN1KMT2A | |
| SCHEMBL3217467 | 0.81 | TSHR (0.31) | — | |
| SCHEMBL1292539 | 0.81 | PIK3CD (0.43) | PIK3CDMEN1KMT2A | |
| SCHEMBL16247245 | 0.78 | PIK3CD (0.46) | PIK3CD | |
| SCHEMBL15745725 | 0.78 | PIK3CD (0.42) | PIK3CDMEN1KMT2A | |
| SCHEMBL11793063 | 0.78 | PIK3CD (0.42) | PIK3CDMEN1KMT2A | |
| SCHEMBL20202518 | 0.78 | — | — | |
| SCHEMBL15696992 | 0.77 | PIK3CD (0.34) | PIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172538-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2020-06-04 | — | — | US | disclosed |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172538-A1 | COMPOUNDS FOR BONE GROWTH | FGF1, FGF2, BMP2 | PIK3CD 3765/4885MEN1 451/4885KMT2A 3833/4885 |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | FGF1, FGF2, BMP2 | PIK3CD 3765/4885MEN1 451/4885KMT2A 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.